MUT056399 is a highly potent new inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. In vitro, MUT056399 was very active against S. aureus strains, including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), linezolid-resistant, and multidrug-resistant strains, with MIC 90 s between 0.03 and 0.12 g/ml. MUT056399 was also active against coagulase-negative staphylococci, with MIC 90 s between 0.12 and 4 g/ml. The antibacterial spectrum is consistent with specific FabI inhibition with no activity against bacteria using FabK but activity against FabI-containing Gram-negative bacilli. In vitro, resistant clones of S. aureus were obtained at a low frequency. All of the resistant clones analyzed were found to contain mutations in the fabI gene. In vivo, MUT056399, administered subcutaneously, protected mice from a lethal systemic infection induced by MSSA, MRSA, and vancomycin-intermediate S. aureus strains (50% effective doses ranging from 19.3 mg/kg/day to 49.6 mg/kg/day). In the nonneutropenic murine thigh infection model, the same treatment with MUT056399 reduced the bacterial multiplication of MSSA and MRSA in the thighs of immunocompetent mice. These properties support MUT056399 as a very promising candidate for a novel drug to treat severe staphylococcal infections.
Infections due to antibiotic-resistant pathogens are a serious health problem globally, such that standard antibiotic therapies have become less effective. More specifically, methicillinresistant Staphylococcus aureus (MRSA) strains are now a major concern in hospital settings worldwide. The emergence of vancomycin-intermediate and -resistant S. aureus (VISA and VRSA), as well as community-acquired MRSA, stresses the need for new antibiotics with new mechanisms of action (3, 4, 17, 23, 25) . Fatty acid biosynthesis is the first stage of membrane lipid biogenesis and represents a vital aspect of bacterial physiology (8, 21) . In most bacteria, a series of small soluble proteins known as fatty acid synthase (FAS) type II enzymes produce a number of essential lipid-containing components included in the cell membrane. Among the FAS type II enzymes, the NADH-dependent trans-2-enoyl-acyl carrier protein (ACP) reductase FabI has been shown to be essential for the growth of S. aureus and Escherichia coli (20, 22) . FabI is a key regulator in controlling the elongation of the acyl chain for saturated fatty acid and unsaturated fatty acid (UFA) synthesis in bacteria (42, 43) . On this basis and due to the absence of a eukaryotic orthologue, FabI was identified as a novel and promising candidate drug target (28, 34) . Several enoyl-ACP reductases were found in bacterial species (30, 31, 34) . For instance, FabK found in streptococci is radically different from FabI at the primary sequence level (29, 36) . Consequently, a specific FabI inhibitor is expected to be a narrow-spectrum agent specific for bacterial species dependent on FabI for fatty acid synthesis, such as S. aureus and coagulase-negative staphylococci, as well as some Gram-negative enterobacteria (30) .
A rational molecular design strategy has been set up using the available structural data on FabI bound to a very simple molecule such as triclosan (26, 32, 38, 39) . This drug discovery program has successfully generated a new series of inhibitors (aryloxy-phenol series) exhibiting strong antistaphylococcal activities, with MUT056399 (also named FAB001) ( Fig. 1 ) being identified as one of the most potent compounds.
MATERIALS AND METHODS
The compound used in this study was MUT056399, synthesized by Mutabilis. The reference compounds vancomycin, linezolid, quinupristin-dalfopristin, levofloxacin, clindamycin, clarithromycin, and triclosan were purchased from commercial sources. Strains from the Mutabilis internal collection were collected from different sources, i.e., the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) and the ATCC (LGC Promochem). Glycopeptideintermediate S. aureus (GISA) and VISA JUS strains were obtained from the French National Reference Center for S. aureus in Lyon. S. aureus strain ATCC 700699 was used after isolation on vancomycin at 4 g/ml to maintain the VISA phenotype (MICs of vancomycin ranging from 4 to 8 g/ml).
The strains and isolates used in susceptibility and spectrum studies came from the Quotient Bioresearch internal collection. The MICs of MUT056399 were determined against 118 S. aureus strains, 165 coagulase-negative staphylococci, 31 other bacterial species listed in Table 1 , Candida albicans ATCC 90028, and Candida glabrata NCPF 3309.
In vitro antibacterial activity. The MICs were determined according to CLSI methodology against aerobic bacteria and Neisseria gonorrhoeae (10) , Listeria monocytogenes, Corynebacterium jeikeium (14) , Mycobacterium fortuitum (12) , Haemophilus ducreyi (15) , anaerobes (11) , and yeasts (13 Bactericidal activity was evaluated in time-kill kinetics experiments according to CLSI methods (9) by exposing a mid-log-phase inoculum of 5 ϫ 10 5 CFU/ml to each compound at 4, 16, and 64 times the MIC in broth medium and by counting the viable bacteria at 0, 4, 6, 8, and 24 h. The criterion for a bactericidal effect was a Ն3-log 10 (99.9% killing) decrease in the CFU count at a specified time; a decrease of less than 3 log 10 CFU/ml was interpreted as bacteriostatic activity (9) . Time-kill kinetics experiments in the presence of 50% human serum were performed using bacteria grown in cation-adjusted Mueller-Hinton broth containing 50% human serum from a commercial source.
Resistance mutants. The spontaneous resistance frequency was measured by plating 1 ϫ 10 10 CFU late-log-phase bacteria onto Mueller-Hinton agar plates with and without MUT056399 at 4 times the MIC and incubating them at 35°C for 48 h. Among the MUT056399-resistant clones obtained, two to four clones were selected per strain. After 5 serial passages on nonselective agar medium, the clones displaying a stable resistance phenotype were subject to fabI gene sequencing. Gene amplification and sequencing were performed using the forward primer 5Ј-AAATCAAACATTTATCGTTGTAATACGTTT-3Ј and the reverse primer 5Ј-CAAATAATTTTCCATCAGTCCGATT-3Ј. Sequences of resistant clones were compared to that of the wild-type strain to identify potential mutations.
In vivo antibacterial activity. For the systemic infection model, groups of six female Swiss mice (6 weeks old) were infected by the intraperitoneal route with The murine local infection model described by Andes and Craig (2) was also used to assess MUT056399 in vivo activity. In the thigh infection model, groups of five immunocompetent female Swiss mice (6 weeks old) were infected by the intramuscular route with either MRSA or MSSA strains at inoculum levels ranging from 3.1 ϫ10 6 to 9.1 ϫ10 6 CFU/mouse. One group of mice was used to determine the bacterial count in the thigh just before treatment started, the starting inoculum. At 1.5 h postinfection, the mice were treated with a single subcutaneous administration of MUT056399 in a 20% HPBCD and 1% glucose solution at various dose levels ranging from 25 mg/kg to 75 mg/kg. A positive reference control group was administered linezolid by the subcutaneous route at 50 mg/kg in 0.9% NaCl at 1.5 h postinfection. After 20 h, the thigh muscles were recovered and bacterial counting was performed. The bacteriostatic dose is defined as that which controls bacterial multiplication, resulting in a bacterial burden that is comparable to the starting inoculum.
RESULTS
In vitro antibacterial activity of MUT056399. MUT056399 is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC 50 s of 12 nM and 58 nM, respectively (7). MUT056399 was very active against the 118 S. aureus strains tested, including MSSA and MRSA isolates and linezolid-resistant and multidrug-resistant strains, with MIC 90 s between Յ0.03 and 0.12 g/ml ( Table 1) . The reference compound linezolid (MIC 90 s, 2 to Ն16 g/ml) was notably less potent than MUT056399.
MUT056399 also exhibited potent activity against coagulasenegative staphylococci, although more elevated MICs were seen with some of the 165 strains of coagulase-negative staphylococci than with S. aureus. This was previously reported with another FabI inhibitor (33) and could be related to a lower susceptibility of some strain of S. epidermidis to triclosan (38) . MUT056399 displayed in vitro antibacterial activity against other bacterial species (Table 1) , in particular against FabIcontaining Gram-negative bacteria such as E. coli, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Helicobacter pylori, and Moraxella catarrhalis. Interestingly, MUT056399 inhibited the replication of several atypical species such as C. trachomatis, Chlamydophila pneumoniae, and L. pneumophila. Finally, MUT056399 was inactive against both C. glabrata and C. albicans, with MICs of Ͼ64 g/ml. The antibacterial spectrum is consistent with specific FabI inhibition with no activity against FabK-containing bacteria (streptococci and enterococci) or bacteria having both FabI and FabK (Pseudomonas aeruginosa and Enterococcus faecalis) or FabL (Bacillus sp.). The higher MICs observed in the susceptible enterobacteria than in S. aureus are probably due to the presence of efflux pumps in these Gram-negative bacteria, as shown for another FabI inhibitor active only in E. coli with its efflux pump deleted (24) . MUT056399 showed slow killing kinetics in vitro at 4 times the MIC, with a reduction in viable bacterial counts of about 2 log 10 CFU/ml after 8 and 24 h of incubation against most of the S. aureus strains tested, including MSSA, MRSA, and VISA strains (data not shown). With MSSA ATCC 29213, the killing rates were similar from 4 to 64 times the MIC, suggesting time-dependent killing by MUT056399 (Fig. 2A) . In the presence of 50% human serum, the MIC of MUT056399 increased by 4-to 16-fold, depending on the strain. This effect could be explained by the strong affinity of MUT056399 for human serum albumin, as determined by high-performance liquid chromatography with 95% binding (18) . MUT056399 also demonstrated slow killing kinetics at 4 times the actual MIC against S. aureus ATCC 29213 in the presence of 50% human serum (Fig. 2B) , although under these conditions, the killing rate of MUT056399 was lower than those of linezolid and vancomycin. . Under these conditions, the cultures were exposed to MUT056399 at 4 ϫ MIC (4 g/ml) (filled circles).
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In vitro resistance to MUT056399. The frequency of spontaneous resistance was assessed in eight S. aureus strains and was found to be low, between 2.5 ϫ 10 Ϫ9 and 7 ϫ 10 Ϫ9 at 4 times the MIC (7). In these experiments, S. aureus clones with reduced susceptibility to MUT056399 were isolated. They fall into two distinct groups, one with MUT056399 MICs of 0.5 to 4 g/ml and another with MICs of Ն32 g/ml (Table 2 ). Susceptibility to vancomycin was not affected, whereas decreased susceptibility to MUT056399 was associated with decreased susceptibility to triclosan. Sequence analysis of the fabI gene of these clones revealed that four types of single-point mutation occurred in the less susceptible variants. Those nucleotide changes resulted in the amino acid substitution A95V in the FabI protein of all of the clones with MUT056399 MICs of Ͼ32 g/ml, whereas the amino acid substitution F204S, I193F, or Y147H was found in the FabI protein of the clones having MUT056399 MICs of 0.5 to 4 g/ml (Table 2) .
In vivo antibacterial activity of MUT056399. In the systemic model of lethal infection of mice, MUT056399 produced a dose-dependent increase in mouse survival at 48 h postinfection with MSSA and MRSA. Mean 50% effective dose (ED 50 ) values ranging from 19.3 to 49.6 mg/kg/day against the different S. aureus strains are reported in Table 3 . Under these conditions, the reference compound vancomycin showed ED 50 s (Table 3) .
DISCUSSION
MUT056399 demonstrated very potent in vitro antibacterial activity against a large number of the staphylococci tested, including methicillin-resistant, linezolid-resistant, and multidrug-resistant strains. MUT056399 was designed as a specific FabI inhibitor, and as expected, MUT056399 showed a spectrum specific for bacterial species which are known to be strictly dependent on the FabI enzyme for fatty acid biosynthesis, including Gram-negative bacteria. This spectrum is in contrast to that of other specific FabI inhibitors such as AFN-1252 and CG400549, which have antibacterial activity only against staphylococci (24, 33) . The spectrum is also different from that of triclosan, which has a broad spectrum of activity against Gram-positive and Gram-negative bacteria, fungi, and Plasmodium falciparum (20, 27) due to its ability to inhibit related ACPs. The less MUT056399-susceptible mutants of S. aureus isolated in vitro contained FabI with mutations in the same amino acid positions as other mutants resistant to FabI inhibitors previously described (22, 40) . These data support the proposed antibacterial mechanism of action of MUT056399 as a specific FabI inhibitor.
In vitro, MUT056399 also showed slow S. aureus killing kinetics in the presence of 50% human serum. This result could indicate that the level of UFA present for 24 h in the culture did not complement the FabI inhibition. Concerns have been raised about compounds targeting fatty acid synthesis due to a report that some Gram-positive bacterial mutants deficient in fatty acid biosynthesis were able to complement auxotrophy for UFA by uptake of UFA from the host (6) . The roles of the multiple FAS type II enzymes have been shown to vary among the different bacterial species (1, 31, 41, 42, 43) . In particular, it was recently demonstrated that FAS type II inhibitors of the elongation cycle (such as specific FabI inhibitors) cannot be overcome by providing S. aureus with exogenous fatty acids, whereas in Streptococcus pneumoniae they can (35) . Furthermore, MUT056399 was found to be very efficacious in vivo by protecting mice against virulent strains of S. aureus, including MSSA, MRSA, and VISA clinical isolates, in two murine infection models. These data, together with other publications of FabI inhibitors (21, 24, 27, 37, 44) , do show that FabI is a validated target and that S. aureus is indeed unable to multiply in the presence of these specific inhibitors in animal models of infection (5, 33) .
The emergence of MRSA and in vitro resistance to vancomycin, combined with reports of clinical failures with this and other antistaphylococcal agents (4, 16, 23) , underscores the need for alternative therapies (17) . In order to address this need, MUT056399 represents a novel antibacterial compound targeting the major Gram-positive pathogen S. aureus and all of its multiresistant variants, such as MRSA, VISA, and VRSA. The key advantage of this compound is its antibacterial activity against a novel molecular target that is essential for the growth of S. aureus, including all drug-resistant variants. Consequently, cross-resistance to MUT056399 and the antibacterial agents currently used in clinical practice to treat staphylococcal infections is unlikely to occur.
